Oragenics (NYSEAMERICAN:OGEN) issued its earnings results on Wednesday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03), Fidelity Earnings reports.
Shares of OGEN traded up $0.01 during trading hours on Thursday, hitting $0.37. The company had a trading volume of 21,095 shares, compared to its average volume of 1,193,495. Oragenics has a one year low of $0.36 and a one year high of $3.74.
Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Oragenics in a report on Tuesday, May 21st.
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Read More: Market Timing – The Benefits and the Danger
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.